BrainStorm Cell Therapeutics Inc.(BCLI),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community - To The Moon

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

BCLI BrainStorm Cell Therapeutics Inc.

Pre-Mkt 10-02 08:00:02 EDT Delay

盘前0.8861

-0.11-11.39%

08:00 EDT

{"stockData":{"symbol":"BCLI","market":"US","secType":"STK","nameCN":"BrainStorm Cell Therapeutics Inc.","latestPrice":1,"timestamp":1790884800000,"preClose":0.95,"halted":0,"volume":17436,"hourTrading":{"tag":"盘前","latestPrice":0.88605,"preClose":1,"latestTime":"08:00 EDT","volume":62,"amount":54.9351,"timestamp":1790942402235,"change":-0.11395,"changeRate":-0.11395,"amplitude":0},"delay":15,"changeRate":0.052631578947368474,"floatShares":9913620,"shares":11034775,"eps":-0.952853,"marketStatus":"Pre-Mkt","change":0.05,"latestTime":"10-02 08:00:02 EDT Delay","open":0.94301,"high":1.08,"low":0.922,"amount":17145.369550000003,"amplitude":0.166316,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"otc":true,"ttmEps":-0.952853,"tradingStatus":1,"nextMarketStatus":{"tag":"Open","tradingStatus":2,"beginTime":1790947800000},"marketStatusCode":1,"adr":0,"listingDate":1052452800000,"exchange":"OTCQB","adjPreClose":1,"volumeRatio":1.759541441944938},"requestUrl":"/m/hq/s/BCLI/wiki","defaultTab":"wiki","newsList":[{"id":"2661276130","title":"BrainStorm Cell Therapeutics Executives Attend Duphat Conference, Pitts Delivers Keynotes","url":"https://stock-news.laohu8.com/highlight/detail?id=2661276130","media":"Reuters","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2661276130?lang=en_us&edition=fundamental","pubTime":"2026-08-24 20:16","pubTimestamp":1787573796,"startTime":"0","endTime":"0","summary":"BrainStorm Cell Therapeutics executives attend DUPHAT conference, Pitts delivers keynotesBrainStorm will attend the DUPHAT pharmaceuticals conference in Dubai on Aug. 25-27, 2026.Executive Chairman Pe","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260824:nNDLJ8bhR:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BCLI","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2659126073","title":"Brainstorm Cell Q2 EPS $(0.35) Down From $(0.34) YoY","url":"https://stock-news.laohu8.com/highlight/detail?id=2659126073","media":"Benzinga Earnings","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2659126073?lang=en_us&edition=fundamental","pubTime":"2026-08-15 04:10","pubTimestamp":1786738257,"startTime":"0","endTime":"0","summary":"Brainstorm Cell (OTC:BCLI) reported quarterly losses of $(0.35) per share. This is a 2.94 percent decrease over losses of $(0.34) per share from the same period last year.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/news/earnings/26/08/61227136/brainstorm-cell-q2-eps-0-35-down-0-34-yoy","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"Brainstorm Cell Q2 EPS $(0.35) Down From $(0.34) YoY","news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","BCLI"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2659264451","title":"BrainStorm Q2 FY26 Net Loss Widens to USD 3.9 Million; G&A Expenses Climb to USD 2.7 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2659264451","media":"Reuters","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2659264451?lang=en_us&edition=fundamental","pubTime":"2026-08-15 04:00","pubTimestamp":1786737643,"startTime":"0","endTime":"0","summary":"BrainStorm Q2 FY26 net loss widens to USD 3.9 million; G&A expenses climb to USD 2.7 millionBrainStorm Cell Therapeutics posted a Q2 net loss of USD 3.9 million, widening from USD 2.9 million a year e","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260814:nNDL73m75W:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","BCLI"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2659264871","title":"Brainstorm Cell Therapeutics Announces Second Quarter 2026 Financial Results and Provides Corporate Update","url":"https://stock-news.laohu8.com/highlight/detail?id=2659264871","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2659264871?lang=en_us&edition=fundamental","pubTime":"2026-08-15 04:00","pubTimestamp":1786737600,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260814:nTUA1V3KX2:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","BCLI"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2659012647","title":"Press Release: BrainStorm Cell Therapeutics Announces Second Quarter 2026 Financial Results and Provides Corporate Update","url":"https://stock-news.laohu8.com/highlight/detail?id=2659012647","media":"Dow Jones","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2659012647?lang=en_us&edition=fundamental","pubTime":"2026-08-15 04:00","pubTimestamp":1786737600,"startTime":"0","endTime":"0","summary":"NEW YORK, Aug. 14, 2026 /PRNewswire/ -- BrainStorm Cell Therapeutics Inc. , a leading developer of adult stem cell therapeutics for neurodegenerative diseases, today announced financial results for the second quarter ended June 30, 2026, and provided a corporate update.\"We continue to advance and complete the preparations necessary to initiate the Phase 3b ENDURANCE study of NurOwn in ALS, supported by an FDA-agreed protocol under a Special Protocol Assessment,\" said Chaim Lebovits, President and Chief Executive Officer of BrainStorm. \"The recent appointment of Peter Pitts as Executive Chairman represents an important enhancement to our leadership. Peter is joining the Company in an active executive capacity and will help lead the regulatory, operational, partnership and capital-markets initiatives surrounding the NurOwn program. His experience as a former senior FDA official brings an additional level of regulatory insight and strategic perspective as we prepare to enter this next pha","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["R","BK4539","LENZ","BK4139","BK4232","BK4007","BK4022","BCLI"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2655892503","title":"BrainStorm Names ex-FDA Official Peter Pitts Executive Chairman, Frenkel Becomes Senior Adviser","url":"https://stock-news.laohu8.com/highlight/detail?id=2655892503","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2655892503?lang=en_us&edition=fundamental","pubTime":"2026-07-31 05:08","pubTimestamp":1785445691,"startTime":"0","endTime":"0","summary":"BrainStorm names ex-FDA official Peter Pitts executive chairman, Frenkel becomes senior adviserBrainStorm Cell Therapeutics named former FDA Associate Commissioner Peter J. Pitts executive chairman, a","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260730:nNDL4QlS57:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BCLI","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2654001481","title":"Brainstorm Appoints Former FDA Associate Commissioner Peter J. Pitts as Executive Chairman","url":"https://stock-news.laohu8.com/highlight/detail?id=2654001481","media":"THOMSON REUTERS","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2654001481?lang=en_us&edition=fundamental","pubTime":"2026-07-28 20:00","pubTimestamp":1785240014,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260728:nTUALTSXB:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","BCLI"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2640182922","title":"Brainstorm Cell Therapeutics director Peter J. Pitts files initial beneficial ownership statement","url":"https://stock-news.laohu8.com/highlight/detail?id=2640182922","media":"Reuters","labels":["executive","shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2640182922?lang=en_us&edition=fundamental","pubTime":"2026-06-04 05:38","pubTimestamp":1780522687,"startTime":"0","endTime":"0","summary":"Brainstorm Cell Therapeutics director Peter J. Pitts reported a 150,000-share stock option expiring May 25, 2036 with a $0.68 exercise price.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Brainstorm Cell Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on June 03, 2026, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260603:nNDL4ww3nf:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive,shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","BCLI"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2638169885","title":"BrainStorm Cell Therapeutics appoints former FDA official Peter Pitts to board","url":"https://stock-news.laohu8.com/highlight/detail?id=2638169885","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2638169885?lang=en_us&edition=fundamental","pubTime":"2026-05-28 19:46","pubTimestamp":1779968774,"startTime":"0","endTime":"0","summary":"BrainStorm Cell Therapeutics appointed former FDA Associate Commissioner Peter J. Pitts to its board, effective immediately.Pitts is president and co-founder of the Center for Medicine in the Public Interest.The appointment comes as the company prepares to launch its Phase 3b ENDURANCE trial of NurOwn for ALS, subject to funding.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260528:nNDLc6tBjD:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","BCLI"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2638698833","title":"Brainstorm Cell Therapeutics Appoints Former FDA Associate Commissioner Peter J. Pitts to Board of Directors","url":"https://stock-news.laohu8.com/highlight/detail?id=2638698833","media":"THOMSON REUTERS","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2638698833?lang=en_us&edition=fundamental","pubTime":"2026-05-28 19:45","pubTimestamp":1779968700,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260528:nTUA5HLKBN:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","BCLI"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2636085515","title":"Press Release: BrainStorm Cell Therapeutics Announces Aggregate of $400,000 in Private Placements Priced at Premium to Market","url":"https://stock-news.laohu8.com/highlight/detail?id=2636085515","media":"Dow Jones","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2636085515?lang=en_us&edition=fundamental","pubTime":"2026-05-19 20:00","pubTimestamp":1779192000,"startTime":"0","endTime":"0","summary":"$2.4 Million in H1 2026 Capital Raises Ahead of Phase 3b ENDURANCE Trial. NEW YORK, May 19, 2026 /PRNewswire/ --  May 19, 2026 -- BrainStorm Cell Therapeutics Inc. , a leading developer of adult stem cell therapies for neurodegenerative diseases, today announced that in May it entered into definitive agreements for a private placement yielding gross proceeds of $400,000.The transactions were priced at $0.95 per share, representing a 37.6% premium over the previous day's closing price of $0.69. Investors will also receive 120% warrant coverage with an exercise price of $1.45 per share and a five-year term from the date of issuance. Two of the private placements for an aggregate of $200,000 in gross proceeds closed on May 11, 2026; the final May private placement closed on May 18, 2026.","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0267386448.USD","BK4534","LU0971096721.USD","BK4139","LU1244550221.USD","LU0158827781.USD","BK4232","LU1988902786.USD","LU1732800096.USD","LENZ","LU1791710400.SGD","LU1244550494.USD","LU0528227936.USD","BK4022","LU0795875086.SGD","LU0106261372.USD","BK4081","BK4539","LU0882574139.USD","LU2357305700.SGD","LU0006306889.USD","LU1162221912.USD","LU0912757837.SGD","LU1244550577.SGD","LU1548497426.USD","LU2111349929.HKD","LU1064131342.USD","BK4588","LU1989772840.SGD","BK4516","BCLI","LU2089283258.USD","LU1720051108.HKD","BK4007","BK4504","EMA","LU0795875169.SGD","LU0158827948.USD","LU0210528500.USD","LU0390134368.USD","LU2089284900.SGD","LU0234570918.USD","R","LU0106831901.USD","LU2264538146.SGD","IE00BKVL7J92.USD","LU1720051017.SGD","BK4127","LU0053666078.USD","IE00BZ1G4Q59.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635374920","title":"Brainstorm Cell Q1 EPS $(0.19) Beats $(0.36) Estimate","url":"https://stock-news.laohu8.com/highlight/detail?id=2635374920","media":"Benzinga Earnings","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2635374920?lang=en_us&edition=fundamental","pubTime":"2026-05-16 04:12","pubTimestamp":1778875974,"startTime":"0","endTime":"0","summary":"Brainstorm Cell (OTC:BCLI) reported quarterly losses of $(0.19) per share which beat the analyst consensus estimate of $(0.36) by 47.22 percent. This is a 57.78 percent increase over losses of $(0.45) per share from the","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/news/earnings/26/05/52615503/brainstorm-cell-q1-eps-0-19-beats-0-36-estimate","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"Brainstorm Cell Q1 EPS $(0.19) Beats $(0.36) Estimate","news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","BCLI"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635037600","title":"BrainStorm Q1 FY26 net loss narrows to $2.13 million; loss per share improves to $0.19","url":"https://stock-news.laohu8.com/highlight/detail?id=2635037600","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2635037600?lang=en_us&edition=fundamental","pubTime":"2026-05-16 04:06","pubTimestamp":1778875605,"startTime":"0","endTime":"0","summary":"BrainStorm Cell Therapeutics posted a net loss of USD 2.13 million, narrowing from USD 2.86 million a year earlier; loss per share improved to USD 0.19 from USD 0.45.Research and development spending fell to USD 762,000 from USD 1.3 million, while general and administrative expense dropped to USD 1.28 million from USD 1.79 million.Cash, cash equivalents, and restricted cash stood at about USD 200,000 at March 31, down from about USD 300,000 at Dec. 31.Preparations continued for planned Phase 3b ENDURANCE study of NurOwn in ALS, designed to enroll about 200 participants with a 24-week randomized segment followed by a 24-week open-label extension.CEO Chaim Lebovits said site activation and regulatory engagement are progressing, with manufacturing and enrollment expected to follow subject to securing necessary financing.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, th","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260515:nNDL5ykzrX:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BCLI","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635376470","title":"Press Release: BrainStorm Cell Therapeutics Announces First Quarter 2026 Financial Results and Provides Corporate Update","url":"https://stock-news.laohu8.com/highlight/detail?id=2635376470","media":"Dow Jones","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2635376470?lang=en_us&edition=fundamental","pubTime":"2026-05-16 04:05","pubTimestamp":1778875500,"startTime":"0","endTime":"0","summary":"\"The team at BrainStorm is focused on completing the final steps required to initiate our planned Phase 3 ENDURANCE study of NurOwn in ALS,\" said Chaim Lebovits, President and CEO. \"Site activation and regulatory engagement are all progressing, and, subject to securing the necessary financing, we are well positioned to move into manufacturing and enrollment phases. ENDURANCE is designed to enroll patients with earlier-stage disease, where NurOwn's mechanism has the greatest opportunity to demonstrate benefit. ALS is a devastating illness with limited therapeutic options, and we remain committed to the community to complete NurOwn's development and make it available to those who need it.\". -- BrainStorm continues its preparations for the Phase 3b ENDURANCE study of. NurOwn, with clinical sites on standby and manufacturing and operational. activities well underway. The planned study is expected to enroll. approximately 200 participants across leading ALS centers and is designed. as a two","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BCLI","LENZ","BK4139","BK4022","BK4007","R","BK4539","BK4232"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2624559776","title":"Brainstorm Cell Q4 EPS $(0.20) Beats $(0.37) Estimate","url":"https://stock-news.laohu8.com/highlight/detail?id=2624559776","media":"Benzinga Earnings","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2624559776?lang=en_us&edition=fundamental","pubTime":"2026-04-01 06:49","pubTimestamp":1774997354,"startTime":"0","endTime":"0","summary":"Brainstorm Cell (OTC:BCLI) reported quarterly losses of $(0.20) per share which beat the analyst consensus estimate of $(0.37) by 45.95 percent. This is a 60.78 percent increase over losses of $(0.51) per share from the","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/news/earnings/26/03/51588093/brainstorm-cell-q4-eps-0-20-beats-0-37-estimate","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"Brainstorm Cell Q4 EPS $(0.20) Beats $(0.37) Estimate","news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","BCLI"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2624853753","title":"BrainStorm FY25 net loss narrows to $10.3 million","url":"https://stock-news.laohu8.com/highlight/detail?id=2624853753","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2624853753?lang=en_us&edition=fundamental","pubTime":"2026-04-01 04:03","pubTimestamp":1774987389,"startTime":"0","endTime":"0","summary":"BrainStorm Cell Therapeutics posted a full-year net loss of USD 10.3 million.NurOwn Phase 3b ENDURANCE study planning continued, targeting about 200 participants pending funding.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260331:nNDL6TjLP2:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BCLI","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2624537869","title":"Press Release: BrainStorm Cell Therapeutics Announces Full Year 2025 Financial Results and Provides Corporate Update","url":"https://stock-news.laohu8.com/highlight/detail?id=2624537869","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2624537869?lang=en_us&edition=fundamental","pubTime":"2026-04-01 04:01","pubTimestamp":1774987260,"startTime":"0","endTime":"0","summary":"Strategic $2.0 million post year-end financing and re-rating of BCLI shares underscore market confidence. Company highlights durable long-term survival in Expanded Access Program  cohort supporting Phase 3b patient selection and inclusion criteria. NEW YORK, March 31, 2026 /PRNewswire/ -- BrainStorm Cell Therapeutics Inc. , a leading developer of adult stem cell therapeutics for neurodegenerative diseases, today announced financial results for the full year ended December 31, 2025, and provided a corporate update.-- A Citizen Petition was filed with the FDA by representatives of the ALS. community. The petition requests a renewed regulatory review of the data. supporting NurOwn. BrainStorm acknowledges the petition as a constructive. development that underscores the continued interest in NurOwn's potential. therapeutic value. The Company did not participate in the drafting or. -- In the Expanded Access Program , 50% of patients  remain alive","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0795875169.SGD","LU0106261372.USD","BK4139","LU1989772923.USD","LU0006306889.USD","LU2089284900.SGD","LU1244550221.USD","LU1548497426.USD","LU0106831901.USD","BK4539","LU2271345857.HKD","LABU","LU0971096721.USD","LU1720051017.SGD","LU1074936037.SGD","BK4022","EMA","LU0225283273.USD","LU0320765646.SGD","BK4007","LU1668664300.SGD","LU1989772840.SGD","BK4516","LU1363072403.SGD","LU2357305700.SGD","R","BCLI","LU2111349929.HKD","LU2347655156.SGD","LENZ","LU1732799900.SGD","BK4588","LU0882574139.USD","LU1162221912.USD","LU2028103732.USD","BK4127","BK6507","LU2023251221.USD","BK4081","BK4232","LU0098860793.USD","BK4504","LU0314104364.USD","NPW.SI","LU1244550494.USD","LU0267386448.USD","IE00BKVL7J92.USD","BK4585","LU1732800096.USD","BK4534"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2622980815","title":"Top News Today/Canada: Government Records C$5.07 Billion Budget Deficit","url":"https://stock-news.laohu8.com/highlight/detail?id=2622980815","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2622980815?lang=en_us&edition=fundamental","pubTime":"2026-03-28 04:30","pubTimestamp":1774643400,"startTime":"0","endTime":"0","summary":"Canada recorded a deficit in January similar to the year-ago period, as both tax revenue and government spending declined in the month.Canada had a budget deficit of C$5.07 billion in January, the Department of Finance said Friday in its monthly Fiscal Monitor publication. This is largely in line with the C$5.13 billion deficit posted in January of last year. With just two months left in the 2025-26 fiscal year, Canada's budget deficit sits at C$31.21 billion, an increase of about 16% from the comparable year-ago period.The Liberal government's annual budget plan, issued in November, projected a C$78.3 billion deficit in the current fiscal year. Historically, finance ministry data tends to show sizable deficits in the month of March, or the last month of the fiscal year, due to adjustments to tax receipts.Statistics Canada Estimates Wholesale Trade Rose 2.3% in February. The estimate incorporates wholesale transactions excluding petroleum products, oilseeds and grains. The data agency ","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4585","HQI","ANNX","BK4161","INLX","BK4139","AQMS","CVV","BCLI","CFA.SI","GALT","BCAX","FTHM","AIRJ","BK4147","BK4079","BK4120","BK4097","BK4081","CYCN","IEF","BK4588","BK4130","GNE"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2614048528","title":"Brainstorm Cell Therapeutics Secures $1M Private Placement at $0.60 a Share","url":"https://stock-news.laohu8.com/highlight/detail?id=2614048528","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2614048528?lang=en_us&edition=fundamental","pubTime":"2026-02-26 19:22","pubTimestamp":1772104978,"startTime":"0","endTime":"0","summary":"Brainstorm Cell Therapeutics Inc. said it entered into a second definitive agreement for a $1 million strategic private placement, bringing its total capital raised in February 2026 to $2 million. The company priced common stock at $0.60 per share and included 120% warrant coverage with a $1.00 exercise price, with the investment to be funded in up to eight staged payments. Proceeds will be used for working capital and to support regulatory and clinical development, including preparatory work for a planned Phase 3b trial of NurOwn.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Brainstorm Cell Therapeutics Inc. published the original content used to generate this news brief via PR Newswire  on February 26, 2026, and is solely responsib","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260226:nNDL3hFWQX:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","BCLI"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.brainstorm-cell.com","description":"Brainstorm Cell Therapeutics Inc., a biotechnology company, engages in the development and commercialization of autologous cellular therapies for the treatment of neurodegenerative diseases. The company, through its NurOwn proprietary cell therapy platform, leverages cell culture methods to induce autologous bone marrow-derived mesenchymal stem cells to secrete high levels of neurotrophic factors, modulate neuroinflammatory and neurodegenerative disease processes, promote neuronal survival, and enhance neurological function. It is developing NurOwn, which has completed Phase III clinical trial for the treatment of amyotrophic lateral sclerosis; Phase II clinical trial for the treatment of progressive multiple sclerosis; and for the treatment of alzheimer's disease, as well as for other neurodegenerative diseases. The company was formerly known as Golden Hand Resources Inc. and changed its name to Brainstorm Cell Therapeutics Inc. in November 2004. Brainstorm Cell Therapeutics Inc. was incorporated in 2000 and is headquartered in New York, New York.","exchange":"OTCQB","name":"BrainStorm Cell Therapeutics Inc.","nameEN":"BrainStorm Cell Therapeutics Inc."},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.50.1","shortVersion":"4.50.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"BrainStorm Cell Therapeutics Inc.(BCLI),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest BrainStorm Cell Therapeutics Inc.(BCLI) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"BrainStorm Cell Therapeutics Inc.,BCLI,BrainStorm Cell Therapeutics Inc.股票,BrainStorm Cell Therapeutics Inc.股票老虎,BrainStorm Cell Therapeutics Inc.股票老虎国际,BrainStorm Cell Therapeutics Inc.行情,BrainStorm Cell Therapeutics Inc.股票行情,BrainStorm Cell Therapeutics Inc.股价,BrainStorm Cell Therapeutics Inc.股市,BrainStorm Cell Therapeutics Inc.股票价格,BrainStorm Cell Therapeutics Inc.股票交易,BrainStorm Cell Therapeutics Inc.股票购买,BrainStorm Cell Therapeutics Inc.股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"BrainStorm Cell Therapeutics Inc.(BCLI),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest BrainStorm Cell Therapeutics Inc.(BCLI) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}